SanegeneBio, a clinical-stage biotechnology company focused on genetic medicines, has secured $110,000,000 in investment from a syndicate of private equity investors. This significant funding round will accelerate the company's efforts to develop best-in-class RNA interference (RNAi) therapies for obesity, cardiometabolic, and autoimmune diseases. The investment underscores the confidence in SanegeneBio’s pioneering approach to addressing global unmet medical needs.
Founded in 2021 by industry veterans with deep RNAi expertise, SanegeneBio operates as a fully integrated entity with headquarters in Boston and R&D operations spanning both the U.S. and China. The company's core approach leverages its proprietary LEAD™ (Ligand and Enhancer Assisted Delivery) technology platform. This innovative platform enables tissue-specific silencing of disease-driving genes in critical areas such as the liver, adipose tissue, muscle, and immune cells, with the aim of achieving therapeutic effects through safe, infrequent subcutaneous dosing.
The newly raised capital is earmarked to advance SanegeneBio's pipeline of genetic medicines, expand its research and development capabilities, and further scale its operational footprint. By strengthening its resources, SanegeneBio aims to accelerate the progression of its clinical programs and enhance its discovery efforts. This investment is crucial for supporting the company’s ambitious goals in developing novel treatments.
This substantial funding injection is expected to significantly propel SanegeneBio’s commitment to bringing transformative RNAi therapies to patients worldwide. The company anticipates that this investment will enable it to expedite the development of its innovative genetic medicines and continue its trajectory towards becoming a leader in the RNAi therapeutic landscape.
